Halozyme Therapeutics Inc (HALO)

13.94
NASDAQ : Health Care
Prev Close 13.99
Day Low/High 13.69 / 14.04
52 Wk Low/High 7.70 / 15.20
Avg Volume 1.29M
Exchange NASDAQ
Shares Outstanding 129.80M
Market Cap 1.82B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Halozyme, Omeros, Aralez

Biotech Premarket Movers: Halozyme, Omeros, Aralez

Halozyme Therapeutics, Omeros and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Slowly but Surely, Post-Fed Euphoria Dissipates

Slowly but Surely, Post-Fed Euphoria Dissipates

The market response to the Fed was quite extreme, although there really wasn't any major development.

There Should Be More Selling

There's certainly enough weakness in the market.

Constellation Brands, Halozyme Therapeutics: Jim Cramer's Top Takeaways

Constellation Brands, Halozyme Therapeutics: Jim Cramer's Top Takeaways

Jim Cramer interviews CEOs from Constellation and Halozyme about their businesses and their stocks' wild ride.

Retail, Politics and Bonds Signal Trend Changes: Cramer's 'Mad Money' Recap (Thursday 1/5/17)

Retail, Politics and Bonds Signal Trend Changes: Cramer's 'Mad Money' Recap (Thursday 1/5/17)

Jim Cramer says this rally relies on a speedy end to regulation, fast repatriation of foreign money and corporate tax reform.

Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints

Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints

-Study shows statistically significant improvement in progression-free survival (PFS) in all evaluable patients and in patients with high levels of hyaluronan (HA), a potential new biomarker-

First Week Of HALO February 2017 Options Trading

First Week Of HALO February 2017 Options Trading

Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.

Halozyme Therapeutics Reaches Analyst Target Price

Halozyme Therapeutics Reaches Analyst Target Price

In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $13.15, changing hands for $13.83/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types

Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types

Phase 1b/2 studies will evaluate Halozyme's investigational drug, PEGPH20 with Genentech's anti-PDL1 Tecentriq® (atezolizumab)

PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients

PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients

Pancreatic Cancer Action Network's Precision Promise Initiative to Incorporate Halozyme's PEGPH20 for Patients Identified With High Levels of Hyaluronan

Are Your Stocks Just Running in Place?

Are Your Stocks Just Running in Place?

If investing is like a horserace, you can change horses in the middle of the race.

Bullish & Bearish Reversals for the Week

Bullish & Bearish Reversals for the Week

Energy and consumer defensive names dominate on the bearish side.

Netflix Can Break out Soon

Netflix Can Break out Soon

Plus, charts from ALGN, HALO and CME.

One Reason Why Halozyme Therapeutics (HALO) Stock Is Climbing Today

One Reason Why Halozyme Therapeutics (HALO) Stock Is Climbing Today

Halozyme Therapeutics (HALO) stock price target was raised at Piper Jaffray on Friday due to the long-term value of its Enhanze products.